Keen Eye and Ultivue Announce Collaborative Agreement to Propel Multiplex and Spatial Analysis in Clinical Research
Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.
Ultivue develops unique solutions for use in mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples. This technology combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
Ultivue recognizes the need for dedicated and custom AI models to analyze the complexity of mIF data at scale and to provide improved turn-around times and consistent readouts across large cohorts “We are looking forward to accelerating data generation for biopharma customers from mIF kits by partnering with Keen Eye. We can jointly support more scalable workflows which will allow us to meet increasing demand in clinical trials.” said Florian Leiss, Ph.D. Vice President Digital Health Strategies at Ultivue.
Keen Eye is an AI Platform company dedicated to deliver accurate, standardized, and undiscovered tissue insights in research and clinical development using Deep Learning histopathology digital image analysis. Its proprietary models dedicated for spatial exploration of tumor microenvironment give access to reliable tissue segmentation, biomarker quantification, cell population profiling, and morphological discovery.
Thanks to Ultivue’s pre-optimized assays, the high accuracy achieved for every biomarker will drastically reduce errors during quantification steps as phenotypes combine several biomarkers. As Dr. Sylvain Berlemont, Keen Eye’s founder and CEO says, “We are thrilled to expand our application portfolio combined with best-in-class Ultivue mIF assays to biopharma companies and CROs. This partnership will undeniably support our customers to fully extend reproducibility and scalability throughout their clinical research.”.
About Keen Eye
Keen Eye is a health technology company based in Paris, aiming to bring AI into every research laboratory, CRO and pharmaceutical company, for the benefit of biologists, pathologists, and patients. Keen Eye is building decision-support and GCLP-compliant image analysis solutions relying on Deep Learning technology through web-based platforms. Keen Eye strives to support the development of new therapies with better, faster, and accurate analytics. Learn more at keeneye.ai.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005704/en/
Contact information
Keen Eye
Sylvain Berlemont, Ph.D
CEO and Founder
sylvain.berlemont@keeneye.ai
Ultivue
Florian Leiss Ph.D
Vice President Digital Health Strategies
Florian.leiss@ultivue.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Envoy Gateway Makes Using Envoy Proxy Easier for Developers and Reverses Fragmentation16.5.2022 06:01:00 CEST | Press release
Members of the steering group for Envoy Gateway (EG), including Envoy creator Matt Klein and representatives from Ambassador Labs, Fidelity Investments, Tetrate, and VMware, Inc., today announced their joint commitment to the project, which launched today at KubeCon + CloudNativeCon, Europe 2022, under the auspices of the Cloud Native Computing Foundation® (CNCF®). Envoy Gateway is a new effort within the Envoy proxy open source project to simplify Envoy use in cloud-native application development. Envoy Gateway will reduce existing, redundant efforts around Envoy and make it much easier for application developers to use Envoy as a basic API gateway “out of the box” and as a Kubernetes Ingress controller. Exposing a simplified set of APIs, and implementing the Kubernetes Gateway API, EG makes it easier to extend Envoy. Developers will now have a cost-free, unfettered way to provide external access to their work in progress. At the same time, Envoy Gateway will not replace API managemen
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis15.5.2022 18:41:00 CEST | Press release
Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was published in The New England Journal of Medicine (NEJM). The promising 12-week data that showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF) will also be presented at the American Thoracic Society (ATS) International Conference Breaking News session on May 16 in San Francisco.1 “These encouraging, early data showed that treatment with BI 1015550 slowed the rate of lung function decline in patients who were not on approved antifibrotics, as well as those who were taking existing antifibrotic therapy,” commented Luca Richeldi, Professor of Respiratory Medicine at the Università Cattolica del Sacro Cuore in Rome, Italy, and the Principal Investigator on the trial. The primary endpoint of the trial was the change from baseline in forced vital capacity (FVC) – meaning the maximum amount of air (m
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202213.5.2022 13:24:00 CEST | Press release
Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2022. Since the beginning of the year, the Group has recorded a consolidated turnover amounting to €440.9 million, an increase of 25.1% compared to the corresponding data for 2021. All indicators are positive for the period. In the first quarter of 2022 the consolidated EBITDA was €70.9 million compared to €59.6 million in 2021, equal to 16.1% of the turnover. EBIT, from January to March, was €57.7 million (€47.9 million in 2021), and is equal to 13.1% of the turnover. The profit before tax, from January to March, was €59.4 million (€47.6 million in 2021), equal to 13.5% of the turnover. The net financial position of the Group on 31 March 2022 is also positive by 279.7 million. The net financial position on 31 December 2021 was positive for €193.2 million. The comparison with the figures recorded at the end of March 2020 is even sharper. Over the past 24 months, first-quarter turnover inc
Tecnotree Launches Total Digital Transformation Suite for Enterprises and Customers of MTN Ghana13.5.2022 12:00:00 CEST | Press release
Tecnotree, a Finnish-based global provider of digital transformation solutions for Communication Service Providers (CSPs) and Digital Service Providers (DSPs), announced the launch of its digital transformation stack, for enterprise and consumer businesses with MTN Ghana, one of the leading telecommunications service providers in Ghana with over 25.3 million subscribers. This transformation for B2B and B2C empowers the operator with rapid response capabilities, allowing it to meet its enterprise market demand and deliver augmented customer experiences at a reduced cost. Tecnotree’s Digital Transformation Suite 5 product stack is completely TM Forum compliant and deploys a micro-services-based architecture with built-in features for price approvals and overriding, on-boarding and monitoring of cash flow orders via the Customer 360 view, enabling self-care features for consumers and enterprises to manage their accounts, monitor onboarding, raise tickets and service requests. In addition,
Electric Truck Starts Operations at PUMA’s Warehouse in California13.5.2022 09:35:00 CEST | Press release
Sports company PUMA has started transferring goods from the port of Los Angeles to its warehouse in Torrance, CA, with a fully electric truck, an initiative, which is part of the company’s strategy to reduce carbon emissions throughout its business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220513005146/en/ Sports company PUMA has started transferring goods from the port of Los Angeles to its warehouse in Torrance, CA, with a fully electric truck, an initiative, which is part of the company’s strategy to reduce carbon emissions throughout its business. (Photo: Business Wire) The Freightliner truck, which is operated by PUMA’s drayage partner NFI, is a first test vehicle. By the third quarter of 2022, the company expects to have five electric trucks in operation to carry goods from the port to the warehouse. “For us this is a huge step towards cleaner logistics. Instead of using an LNG or a clean diesel truck, we can now